Prevalence of Hyperparathyroidism among Dialysis Patients in Baghdad Teaching Hospital
DOI:
https://doi.org/10.51699/ijhsms.v3i4.127Keywords:
Chronic kidney disease, Epidemiology, Parathyroid hormone, Hyperparathyroidism, Pathogenesis, PrevalenceAbstract
Chronic kidney disease is common due to the high prevalence of its main causes. Many pathological changes occur in these patients. Hyperparathyroidism is one of the most common pathologies reported in chronic kidney disease patients. High prevalence rates have been reported worldwide in previous studies, and different factors have been implicated to be associated with Hyperparathyroidism. The aim of this study is to assess the prevalence of hyperparathyroidism among Iraqi patients with chronic kidney disease on hemodialysis therapy and to identify the factors associated with hyperparathyroidism. This was a cross-sectional study with analytic utility performed in in Baghdad Teaching Hospital, Dialysis Center during the period from June 2020 to March 2021. The study included 100 patients (60 males and 40 females). Patients with one or more of the following were excluded: primary hyperparathyroidism. Known parathyroid gland disease, malignancy, bone diseases, Kidney transplantation, or history of parathyroid surgery. Data was collected using a data collection form, and analysis was performed using the statistical package for Social Sciences version 26 (SPSS 26). Appropriate statistical tests were applied accordingly at a level of significance of 0.05. The mean age of the patients was 53.1 ± 14.2 (range: 18 – 80) years, male to female ratio was 1.5 to one. Prevalence of hyperparathyroidism was 33%. No significant association between hyperparathyroidism and each of age, the cause of CKD, or comorbidities. Hyperparathyroidism was more frequent in females (P<0.05). Higher prevalence of Hyperparathyroidism was reported among users of calcium tab supplementation\chelating, vitamin D, and Cinacalcit (P<0.05). Hyperparathyroidism was frequent among Iraqi CKD patients treated by hemodialysis in a rate of 33%. Higher prevalence of Hyperparathyroidism appeared to be associated with female gender, longer duration on hemodialysis, using calcium supplementation/chelating, vitamin D, and Cinacalcit.
References
M. El Nahas and A. K. Bello, "Chronic kidney disease: The global challenge," Lancet, vol. 365, no. 9456, pp. 331–340, 2005. DOI: https://doi.org/10.1016/S0140-6736(05)17789-7
C. Webster, E. V. Nagler, R. L. Morton, and P. Masson, "Chronic kidney disease," Lancet, vol. 389, no. 10075, pp. 1238–1252, 2017. DOI: https://doi.org/10.1016/S0140-6736(16)32064-5
S. Levey and J. Coresh, "Chronic kidney disease," Lancet, vol. 379, no. 9811, pp. 165–180, 2012. DOI: https://doi.org/10.1016/S0140-6736(11)60178-5
J. Bover and M. Cozzolino, "Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: New insights into vitamin D receptor activation," Kidney International Supplements, vol. 1, no. 4, pp. 122–129, Sep. 2011. DOI: https://doi.org/10.1038/kisup.2011.28
R. Lewis, "Mineral and bone disorders in chronic kidney disease: New insights into mechanism and management," Annals of Clinical Biochemistry, vol. 49, no. 5, pp. 432–440, Sep. 2012. DOI: https://doi.org/10.1258/acb.2012.012004
G. Pontoriero, M. Cozzolino, F. Locatelli, and D. Brancaccio, "CKD patients: The dilemma of serum PTH levels," Nephron Clinical Practice, vol. 116, no. 4, pp. c263–c268, 2010. DOI: https://doi.org/10.1159/000318787
G. J. Elder, A. Malik, and K. Lambert, "Role of dietary phosphate restriction in chronic kidney disease," Nephrology (Carlton), vol. 23, no. 12, pp. 1107–1115, Dec. 2018. DOI: https://doi.org/10.1111/nep.13188
A. M. Shaman and S. R. Kowalski, "Hyperphosphatemia management in patients with chronic kidney disease," Saudi Pharmaceutical Journal, vol. 24, no. 4, pp. 494–505, Jul. 2016. DOI: https://doi.org/10.1016/j.jsps.2015.01.009
F. C. Barreto, D. V. Barreto, Z. A. Massy, and T. B. Drüeke, "Strategies for phosphate control in patients with CKD," Kidney International Reports, vol. 4, no. 8, pp. 1043–1056, Jun. 2019. DOI: https://doi.org/10.1016/j.ekir.2019.06.002
A. Owda, H. Elhwairis, S. Narra, H. Towery, and S. Osama, "Secondary hyperparathyroidism in chronic hemodialysis patients: Prevalence and race," Renal Failure, vol. 25, no. 4, pp. 595–602, 2003. DOI: https://doi.org/10.1081/JDI-120022551
W. G. Douthat, M. Castellano, L. Berenguer, M. A. Guzmán, and J. de Arteaga, "High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina," Nefrologia (English Edition), vol. 33, no. 5, pp. 657–666, 2013.
M. Cozzolino, "CKD-MBD KDIGO guidelines: How difficult is reaching the 'target'?," Clinical Kidney Journal, vol. 11, no. 1, pp. 70–72, Feb. 2018. DOI: https://doi.org/10.1093/ckj/sfx116
G. H. Kim, B. S. Choi, D. R. Cha, D. H. Chee, E. Hwang, and H. W. Kim, "Serum calcium and phosphorus levels in patients undergoing maintenance hemodialysis: A multicentre study in Korea," Kidney Research and Clinical Practice, vol. 33, no. 1, pp. 52–57, 2014. DOI: https://doi.org/10.1016/j.krcp.2013.12.003
J. N. Parmar, M. Panjwani, and B. R. Bariya, "Secondary hyperparathyroidism in patients with chronic renal failure attending a tertiary health care hospital: A cross-sectional study in Saurashtra region of Gujarat, India," Journal of Clinical and Diagnostic Research, vol. 15, no. 2, 2021. DOI: https://doi.org/10.7860/JCDR/2021/45776.14573
L. Dayma, D. Ajmera, and S. C. Jelia, "Study of prevalence of secondary hyperparathyroidism in chronic renal failure in Hadoti region, India," Endocrinology and Nutrition, vol. 62, no. 7, pp. 300–305, 2015.
J. C. Bureoa, J. C. Arévalo, J. Antón, G. Adrados, J. L. J. Morales, and N. R. Robles, "Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine," Endocrinologia y Nutricion (English Edition), vol. 62, no. 7, pp. 300–305, 2015.
V. Billa, A. Zhong, J. Bargman, S. Vas, P. Y. Wong, and D. G. Oreopoulos, "High prevalence of hyperparathyroidism among peritoneal dialysis patients: A review of 176 patients," Peritoneal Dialysis International, vol. 20, no. 3, pp. 315–321, 2011. DOI: https://doi.org/10.1177/089686080002000308
M. Fusaro, M. Cozzolino, M. Plebani, G. Iervasi, M. Ketteler, M. Gallieni, and others, "Sevelamer use, vitamin K levels, vascular calcifications, and vertebral fractures in hemodialysis patients: Results from the VIKI study," Journal of Bone and Mineral Research, vol. 36, no. 3, pp. 500–509, 2021. DOI: https://doi.org/10.1002/jbmr.4214
N. K. Yuen, S. Ananthakrishnan, and M. J. Campbel, "Hyperparathyroidism of renal disease," The Permanente Journal, vol. 20, no. 3, pp. 79–83, 2016. DOI: https://doi.org/10.7812/TPP/15-127
H. E. Meyer, J. A. Falch, A. J. Søgaard, and E. Haug, "Vitamin D deficiency and secondary hyperparathyroidism and the association with bone mineral density in persons with Pakistani and Norwegian background living in Oslo, Norway: The Oslo Health Study," Bone, Aug. 2004. DOI: https://doi.org/10.1016/j.bone.2004.04.003
A. Haddad, H. Shibli, M. Hijazat, S. Sheab, A. Bderat, and A. Qdah, "Prevalence of secondary hyperparathyroidism among hemodialysis patients in three Royal Medical Services centers," Journal of the Royal Medical Services, vol. 102, no. 2053, pp. 1–6, 2015.
J. C. Bureoa, J. C. Arévalo, J. Antón, G. Adrados, J. L. J. Morales, and N. R. Robles, "Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine," Endocrinologia y Nutricion (English Edition), vol. 62, no. 7, pp. 300–305, 2015. DOI: https://doi.org/10.1016/j.endoen.2015.08.007
M. Chandran and J. Wong, "Secondary and tertiary hyperparathyroidism in chronic kidney disease: An endocrine and renal perspective," Indian Journal of Endocrinology and Metabolism, vol. 23, no. 4, pp. 391–395, 2019. DOI: https://doi.org/10.4103/ijem.IJEM_292_19
L. Dayma, D. Ajmera, S. C. Jelia, and P. Jain, "Study of the prevalence of secondary hyperparathyroidism in chronic renal failure in Hadoti region, India," International Journal of Research in Medical Sciences, vol. 7, no. 8, pp. 2903–2907, 2019. DOI: https://doi.org/10.18203/2320-6012.ijrms20193144
V. Shankar, M. Kumar, J. Chitrambalam, and S. V. Nair, "A study of secondary hyperparathyroidism in patients with chronic kidney disease in a tertiary care hospital," Endocrinology and Metabolic Syndrome, vol. 6, no. 273, 2017.
A. A. Mansour and H. A. Swaid, "Predictors of secondary hyperparathyroidism in chronic kidney disease stage 3 and 4," Endocrinology and Metabolic Syndrome, vol. 6, no. 273, pp. 1017–2161, 2017.
Y. Xu, M. Evans, M. Soro, P. Barany, and J. J. Carrero, "Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease," Clinical Kidney Journal, vol. 11, no. 1, pp. 1–8, 2021.
S. M. Moe and T. B. Drüeke, "Management of secondary hyperparathyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus products," American Journal of Nephrology, vol. 23, no. 6, pp. 369–379, 2003. DOI: https://doi.org/10.1159/000073945
Z. Zhan, B. Smyth, N. D. Toussaint, N. A. Gray, L. Zuo, and J. R. De Zoysa, "Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study," BMC Nephrology, vol. 20, no. 1, pp. 1–10, 2019. DOI: https://doi.org/10.1186/s12882-019-1438-3
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Amer Jihad Hussein, Jawad Ibrahim Rasheed, Ban Mezher Noaman
This work is licensed under a Creative Commons Attribution 4.0 International License.
